How Much Does Reclast (Zoledronic Acid) Cost in the District of Columbia in 2026?

Reclast Pricing in DC: List Price vs. What You Actually Pay

The number on the label is not the number most patients pay. Novartis sets the wholesale acquisition cost (WAC) for brand-name Reclast at roughly $1,500 per 5 mg infusion [1]. That figure represents the ceiling. Since zoledronic acid lost patent exclusivity years ago, multiple generic versions have entered the market, and DC infusion centers and hospital outpatient pharmacies now stock generics at substantially lower acquisition costs.

The average cash-pay price for generic zoledronic acid across District of Columbia retail and specialty pharmacies in 2026 sits near $600 per infusion [1]. That price typically covers the drug itself. It does not always include the infusion administration fee, which outpatient facilities in DC bill separately (often $150 to $400 depending on the site of service). For an uninsured patient paying entirely out of pocket, the total yearly cost of a single generic zoledronic acid infusion plus administration may land between $750 and $1,000.

Because zoledronic acid is a once-yearly intravenous infusion, its annualized cost compares favorably to oral bisphosphonates that carry lower per-unit prices but require weekly or monthly dosing and have well-documented adherence problems. A 2012 analysis published in Osteoporosis International found that roughly 50% of patients on oral bisphosphonates discontinued therapy within 12 months [2]. One infusion per year removes adherence from the equation.

DC Medicaid Coverage for Zoledronic Acid

DC Medicaid covers Reclast (zoledronic acid) with prior authorization [1]. The District's fee-for-service Medicaid program and its managed care organizations (MCOs), including AmeriHealth Caritas DC and CareFirst Community Health Plan, maintain zoledronic acid on their formularies under the medical benefit rather than the pharmacy benefit because it is a physician-administered injectable.

Prior authorization requirements in DC typically include documentation of a confirmed osteoporosis diagnosis via dual-energy X-ray absorptiometry (DXA) scan showing a T-score of <-2.5 at the hip or spine, or a history of fragility fracture. Some MCOs also require evidence that the patient has tried or cannot tolerate an oral bisphosphonate before approving the IV formulation. The prescribing provider's office submits the PA request, and DC MCOs generally return a decision within 72 hours for non-urgent requests.

For Medicaid beneficiaries who receive approval, cost-sharing is minimal. DC Medicaid does not impose copayments on most outpatient services for adults enrolled in its expansion population, and the infusion administration fee is covered under the medical benefit. Patients who receive a denial can appeal through the MCO's internal grievance process or request a fair hearing through the DC Department of Health Care Finance.

Private Insurance and Medicare Coverage in DC

Most commercial plans available through DC Health Link (the District's ACA marketplace) and employer-sponsored plans in DC process zoledronic acid under the medical benefit (not pharmacy), meaning the drug and its infusion are billed together as an outpatient medical claim [1]. Patient cost-sharing depends on whether the infusion center is in-network, whether the deductible has been met, and the plan's coinsurance rate for specialist services.

A typical DC commercial plan with a $2,000 deductible and 20% coinsurance after deductible might leave a patient responsible for $120 to $200 of the generic infusion cost once the deductible is satisfied. Some plans classify zoledronic acid under a specialty tier with a flat copay of $50 to $150.

Medicare Part B covers zoledronic acid for osteoporosis when administered in a physician's office or hospital outpatient department. After the Part B deductible ($257 in 2025, subject to annual adjustment), Medicare pays 80% of the approved amount, leaving the beneficiary responsible for 20% coinsurance [3]. Medigap plans or Medicare Advantage plans may cover that remaining 20%. The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines identify zoledronic acid as a first-line option for high-fracture-risk patients, which supports medical necessity documentation for insurance submissions [4].

Discount Programs and Savings Cards in DC

Several pathways can reduce out-of-pocket costs for DC residents. The Novartis patient assistance program offers brand-name Reclast at no cost to qualifying uninsured or underinsured patients whose household income falls below 400% of the federal poverty level. Application forms are available through the Novartis Patient Assistance Foundation website, and approval typically takes two to four weeks.

Manufacturer copay savings cards, when available, apply to commercially insured patients only. They do not apply to Medicare, Medicaid, or other federal program beneficiaries (per federal anti-kickback statute restrictions). The card may reduce the patient's copay to as little as $0 for each infusion, though annual benefit caps vary by program year.

Generic zoledronic acid pricing at DC-area infusion centers varies enough that price-shopping is worthwhile. Hospital outpatient departments generally bill at higher facility fees than freestanding infusion suites. Patients who ask their provider to administer the infusion in an office-based setting rather than a hospital outpatient department can sometimes cut the total bill by 30% to 40%.

GoodRx, RxSaver, and similar aggregator platforms list coupon prices for generic zoledronic acid at DC-area pharmacies, though these coupons apply to the drug cost only. The infusion itself is a medical service billed under a separate CPT code (96413 for the first hour of IV infusion), and coupon platforms do not discount that portion.

Compounded Zoledronic Acid in DC

The District of Columbia permits compounding through licensed 503A pharmacies under federal and DC Board of Pharmacy regulations [1]. A 503A pharmacy may compound zoledronic acid for an individual patient with a valid prescription if a medical need exists (for example, an allergy to an inactive ingredient in the commercial product or a non-standard dose requirement).

Compounded zoledronic acid is not a routine cost-saving alternative for most patients. That matters. Unlike oral medications where compounding pharmacies frequently produce lower-cost versions, IV bisphosphonates require sterile compounding under USP 797 standards, which adds significant cost and regulatory overhead. Generic zoledronic acid is already available as a ready-to-infuse solution, reducing the clinical rationale for compounding in most cases.

Patients considering compounded zoledronic acid in DC should confirm that the pharmacy holds a current DC Board of Pharmacy license, compounds under USP 797 sterile compounding standards, and can provide a certificate of analysis for each batch. The FDA's guidance on 503A compounding outlines the federal framework that applies alongside DC's local rules [5].

Telehealth Prescribing and Infusion Access in DC

Telehealth prescribing of zoledronic acid is permitted in the District of Columbia [1]. A licensed prescriber can evaluate the patient, review DXA results and lab work, and write the prescription via a telehealth visit. DC's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person encounters, which means the evaluation visit itself should not cost the patient more simply because it occurred over video.

The infusion itself requires an in-person visit. Zoledronic acid is administered as a 15-minute or longer IV infusion, and the patient needs monitoring for at least 15 minutes afterward for rare but serious adverse reactions including acute-phase reactions and, very rarely, atrial fibrillation [6]. DC has multiple infusion access points: hospital outpatient infusion centers at MedStar Georgetown, MedStar Washington Hospital Center, George Washington University Hospital, and Sibley Memorial Hospital, plus several freestanding infusion suites in the District.

Pre-infusion lab work is non-negotiable. Serum calcium and vitamin D levels must be checked and corrected before the infusion. The Reclast prescribing information states that patients must be adequately supplemented with calcium and vitamin D, and that zoledronic acid is contraindicated in patients with hypocalcemia [7]. Serum creatinine should also be checked, as the drug is contraindicated in patients with creatinine clearance <35 mL/min.

Clinical Evidence: What the HORIZON Trials Showed

Zoledronic acid's efficacy in osteoporosis rests primarily on the HORIZON-Key Fracture Trial (HORIZON-PFT), a randomized, double-blind, placebo-controlled study enrolling 7,765 postmenopausal women with osteoporosis. Over three years, once-yearly zoledronic acid 5 mg IV reduced the risk of morphometric vertebral fractures by 70% (relative risk 0.30; 95% CI, 0.24 to 0.38) and hip fractures by 41% (hazard ratio 0.59; 95% CI, 0.42 to 0.83) [6].

The numbers were striking. The absolute risk reduction for vertebral fracture was 7.6 percentage points (10.9% placebo vs. 3.3% zoledronic acid), yielding a number needed to treat (NNT) of roughly 14 over three years [6].

A companion trial, HORIZON-Recurrent Fracture Trial (HORIZON-RFT), studied 2,127 patients who had sustained a recent low-trauma hip fracture. Zoledronic acid reduced the rate of new clinical fractures by 35% and, notably, reduced all-cause mortality by 28% (p = 0.01), making it one of the few osteoporosis treatments to demonstrate a mortality benefit in a randomized trial [8].

Dr. Dennis Black, lead investigator of HORIZON-PFT at the University of California, San Francisco, stated: "The magnitude of vertebral fracture risk reduction with yearly zoledronic acid was among the largest observed in any osteoporosis treatment trial" [6]. The AACE 2020 guidelines reflect this evidence by recommending zoledronic acid as a first-line option for patients at high fracture risk, including those with a T-score of <-2.5 at the spine or hip, a prior hip or vertebral fracture, or a high FRAX-calculated probability [4].

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women similarly positions IV zoledronic acid alongside oral alendronate, oral risedronate, and denosumab as initial treatment options: "For postmenopausal women at high risk of fracture, we recommend initial treatment with alendronate, risedronate, zoledronic acid, or denosumab" [9].

Practical Considerations for DC Residents

Scheduling the annual infusion is simpler than maintaining a daily or weekly oral medication regimen, but it still requires planning. DC residents should coordinate the infusion with their provider at least two to three weeks in advance to allow time for pre-infusion blood work (calcium, 25-hydroxyvitamin D, creatinine) and to confirm insurance authorization.

The most common side effects after the first infusion include fever, muscle aches, headache, and joint pain, typically beginning within 24 to 72 hours and resolving within three days. These acute-phase reactions occurred in approximately 32% of patients in HORIZON-PFT after the first dose but dropped to 7% after the second yearly dose and 3% after the third [6]. Pretreatment with acetaminophen 650 mg can reduce the severity of these symptoms.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) are rare but serious risks. In the HORIZON-PFT extension study, the incidence of ONJ was 1 case per 14,200 patient-treatment-years of exposure [10]. The risk of AFFs increases with prolonged bisphosphonate use beyond five years, which is why guidelines recommend considering a "drug holiday" after three to six years of IV bisphosphonate therapy in patients who are no longer at very high fracture risk.

DC residents filling a prescription for pre-infusion calcium and vitamin D supplements can obtain these over the counter at any DC pharmacy without a prescription. Standard pre-infusion supplementation is calcium 1,000 to 1,200 mg/day plus vitamin D 800 to 1,000 IU/day for at least two weeks before the infusion, per National Osteoporosis Foundation recommendations [3].

Patients with dental procedures planned should complete invasive dental work before starting zoledronic acid. The American Dental Association recommends a dental examination before initiating IV bisphosphonate therapy [11].